Piramal Pharma enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


25,349	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
806	1,332	389	502	623
22.5	0.0	0.0	—	—
5,495	5,495	4,720	4,559	5,505
30,060	—	—	—	—
4,689	4,164	4,332	4,057	4,882
₹226.50	—	—	—	—

13,660	13,658	12,846	12,470	12,278
40.2%	40.2%	36.7%	36.6%	44.8%
0.18×	—	—	—	—

3.07×	—	—	—	—
25.05×	—	—	—	—
96.24×	—	—	—	—
39.42×	—	—	—	—
9,779	8,869	9,151	8,171	7,082
1,200	922	1,445	1,196	628
312	90.4	628	456	−48.5
—	1,653	892	1,005	484
763	763	228	293	−481
—	763	−35.1	23.4	−481
—	890	664	712	965

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

PPLPHARMA₹191.00

Piramal Pharma Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB SYNGENE GLAND WOCKPHARMA ASTERDM COHANCE LALPATHLAB NATCOPHARMMcap ₹25,349 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	25,348.8
- Cash, Equiv & ST Investments	622.7	501.5	388.5	1,331.7	806.5
+ Minority Interest	—	—	0.0	0.0	22.5
+ Total Debt	5,504.8	4,558.9	4,720.3	5,495.5	5,495.5
Enterprise Value	—	—	—	—	30,060.2
Net Debt (memo)	4,882.1	4,057.4	4,331.7	4,163.8	4,689.0
EV per Share	—	—	—	—	226.50

Total Capital	12,278.3	12,470.2	12,845.7	13,658.1	13,660.2
Total Debt/Total Capital	44.83	36.56	36.75	40.24	40.23
Total Debt/EV	—	—	—	—	0.18

EV/Sales	—	—	—	—	3.07
EV/EBITDA	—	—	—	—	25.05
EV/EBIT	—	—	—	—	96.24
EV/Free Cash Flow	—	—	—	—	39.42
Reference Items — Trailing FY Values
Sales	7,081.6	8,171.2	9,151.2	8,869.1	9,778.6
EBITDA	628.2	1,196.3	1,444.8	921.6	1,200.2
EBIT	-48.5	455.7	628.5	90.4	312.4
Operating Cash Flow	483.9	1,004.5	892.3	1,652.6	—
Free Cash Flow	-480.9	292.5	227.9	762.6	762.6
FCFF (free cash flow to the firm)	-480.9	23.4	-35.1	762.6	—
Capital Expenditure	964.8	712.0	664.4	890.0	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.